Distinct protective host defenses against oral and vaginal candidiasis

Medical Mycology

Volumn 40, Issue 4, 2002, Pages 359-375

  Fidel Jr , Paul L ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Candida albicans; Host defense mechanisms; Immunosuppression; Mucosal candidiasis; Oral candidiasis; Vaginal candidiasis

Indexed keywords

ANTIFUNGAL AGENT; CANDIDA ALBICANS VACCINE; CANDIDA ANTIGEN; CONTRACEPTIVE AGENT; ESTROGEN; NTIBIOTIC AGENT; STEROID; UNCLASSIFIED DRUG;

CANDIDA ALBICANS; CELLULAR IMMUNITY; COMMENSALISM; EPITHELIUM CELL; FEMALE GENITAL SYSTEM; FUNGICIDAL ACTIVITY; GASTROINTESTINAL TRACT; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE STATUS; IMMUNITY; IMMUNOCOMPETENCE; NONHUMAN; OROPHARYNX; PREVALENCE; RECURRENT INFECTION; REVIEW; RISK FACTOR; THRUSH; VAGINA CANDIDIASIS; VAGINA MUCOSA; FEMALE; IMMUNOLOGY; MUCOSAL IMMUNITY; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; RECURRENT DISEASE;

ANIMALIA; CANDIDA; CANDIDA ALBICANS; HUMAN IMMUNODEFICIENCY VIRUS;

CANDIDIASIS, ORAL; CANDIDIASIS, VULVOVAGINAL; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; OPPORTUNISTIC INFECTIONS; RECURRENCE;

EID: 0036668764     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/714031126     Document Type: Review

References (160)

1. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome
2. The pathology of AIDS
3. Candidiasis in the transplant patient
4. Growth of Candida albicans in saliva: Stimulation by glucose associated with antibiotics, corticosteriods and diabetes mellitus
5. Chronic mucocutaneous candidiosis
6. Oral Carriage of Candida in healthy and HIV-seropositive persons
7. Pathogenesis and epidemiology of vulvovaginal candidiasis
8. T cell subsets and INF-gamma production in resistance to systemic candidosis in immunized mice
9. Pathogenesis and treatment of recurrent vulvovaginal candidiasis
10. Refractory mucosal Candidiasis in patients with human immunodeficiency virus infection
11. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidasis
12. T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development
13. Biological role of Th cell subsets in candidiasis
14. Chronic mucocutaneous candidiasis
15. Suppression of Candida albicans by human oral streptococci in gnotobiotic mice
16. Antibody immunity and invasive fungal infections
17. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis
18. Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis
19. Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis
20. Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity
21. Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis
22. Immune responses to Candida albicans in genetically distinct mice
23. Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and susceptible to Candida albicans infections
24. Increased severity of Candida vaginitis in BALB/c nu/nu mice versus the parent strain is not abrogated by adoptive transfer of T cell enriched lymphocytes
25. Genetic basis for protection against experimental vaginal candidiasis by peripheral immunization
26. Strain-dependent migration of lymphocytes to the vaginal mucosa after peripheral immunization
27. Chronic mucocutaneous candidiasis: Model Building in cellular immunity
28. Humoral immunity in vaginal candidiasis
29. Inhibition of Candida-induced lymphocyte proliferation by antibody to Candida albicans
30. A macrophage defect in women with recurrent Candida vaginitis and its reversal in vitro by prostaglandin inhibitors
31. Immunological aspects of candidal vaginitis
32. Cellular immunity of patients with recurrent of refractory vulvovaginal moniliasis
33. Cellular and humoral immune status in women with chronic Candida vaginitis
34. Investigations by cell-mediated immunologic tests and therapeutic trials with thymopentin in vaginal mycoses
35. Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis (RVVC)
36. The study of cell-mediated immune response in recurrent vulvovaginal candidiasis
37. Cellular immunity in recurrent vulvovaginal candidiasis
38. Vaginal colonization or infection with Candida albicans in human immunodeficiency virus-infected women during pregnancy and during postpartum period
39. Immune compromise and prevalence of Candida vulvovaginitis in human immunodeficiency virus-infected women
40. Clinical and microbiological characteristics of symptomatic vulvovaginal candidiasis in HIV-seropositive women
41. Is vulvovaginal candidiasis an AIDS-related illness?
42. Candida-specific systemic cell-mediated immune reactivities in HIV-infected persons with and without mucosal candidiasis
43. Predictors of HIV progression in women
44. Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection
45. Chronic vaginal candidiasis in women with human immunodeficiency virus infection
46. Hierarchical pattern of mucosal Candida infections in HIV- seropositive women
47. Antigen recognition in the female reproductive tract: I. Uptake of intraluminal protein tracers in the mouse vagina
48. Antigen recognition in the female reproductive tract. II. Endocytosis of horseradish peroxidase by langerhans cells in murine vaginal epithelium
49. Homing of a gamma/delta thymocyte subset with homogenous T-cell receptors to mucosal epithelia
50. Phenotypic analysis and gamma/delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium
51. T lymphocytes in the murine vaginal mucosa are phenotypically distinct from those in the periphery
52. γδ_T cells of the murine vagina: T cell response in vivo in the absence of the expression of CD2 and CD28 molecules
53. Activation features of intraepithelial γδ T-cells of the murine vagina
54. + cells
55. CD3+ CD8+ CTL activity within the human female reproductive tract: Influence of stage of the menstrual cycle and menopause
56. Coexpression of CCR5 and IL-2 in human genital but not blood cells: Implications for the ontogeny of the CCR5+ Th1 phenotype
57. Distribution of lymphocytes and adhesion molecules in human cervix and vagina
58. + T cells
59. Resistance of congenitally immunodeficient gnotobiotic mice to vaginal candidiasis
60. Analysis of vaginal cell populations during experimental vaginal candidiasis
61. Use of cellular depletion analysis to examine circulation of immune effector function between the vagina and the periphery
62. Expression of mucosal homing receptor α4β7 is associated with enhanced migration to the Chlamydia-infected murine genital mucosa in vivo
63. Expression of a mucosal-associated integrin may influence the trafficking of a protective MoPn-specific CD4 clone to the genital tract during chlamydial genital infection
64. Identification of homing receptors that mediate the recruitment of CD4 T cells to the genital tract following intravaginal infection with Chlamydia trachomatis
65. Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo-depletion of T lymphocytes
66. Protective immunity against HSV-2 in the mouse vagina
67. Chlamydia trachomatis infection does not enhance local cellular immunity against concurrent Candida albicans vaginal infection
68. γ cell-induced nitric oxide production enhances resistance to mucosal candidiasis
69. Resistance of TCR δ-chain knock-out mice to experimental Candida vaginitis
70. Local production of chemokines during experimental vaginal candidiasis
71. Local Th1/Th2 cytokine production during experimental vaginal candidiasis
72. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses
73. Measurement of T-cell-derived antigen binding molecules and immunoglobulin G specific to Candida albicans mannan in sera of patients with recurrent vulvovaginal candidiasis
74. How do lymphocytes know where to go: Current concepts and enigmas of lymphocytes homing
75. --integrins in lymphocytes homing to mucosal tissues in vivo
76. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin
77. Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis
78. Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans
79. Th1 and Th2 cytokine secretion patterns in murine candidiasis: Association of Th1 responses with acquired resistance
80. CD4+ subset expression in murine candidiasis
81. Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: Evidence for vaginal Th1-type responses following intravaginal challenge with Candida antigen
82. Local immune responsiveness following intravaginal challenge with Candida antigen in adult women at different stages of the menstrual cycle
83. Detection of anti-Candida albicans IgE antibodies in vaginal washes from patients with acute vulvovaginal candidiasis
84. Vaginal eosinophils and IgE antibodies to Candida albicans in women with recurrent vaginitis
85. A localized vaginal allergic response in women with recurrent vaginitis
86. Langerhans cells and T lymphocyte subsets in the murine vagina and cervix
87. Mucosal immunity in the female reproductive tract: Correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation
88. Endocrine regulation of mucosal immunity: Effect of sex hormones and cytokines on the afferent and efferent arms of the immune system in the female reproductive tract
89. Candida-specific antibodies during experimental vaginal candidiasis in mice
90. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies
91. Human natural yeast killer toxin-like andidicidal antibodies
92. Rats clearing a vaginal infection by Candida albicans aquire specific, antibody-mediated resistance to vaginal infection
93. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats
94. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection
95. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody
96. Acute neutropenia decreases inflammation associated with murine vaginal candidiasis but has no effect on the course of infection
97. Regulation of human polymorphonuclear neutrophil (PMN) activity against Candida albicans by large granular lymphocytes via release of a PMN-activating factor
98. Noninhibitory binding of human interleukin-2-activated natural killer cells to the germ tube forms of Candida albicans
99. Epithelial cytokine responses and mucosal cytokine networks
100. Gamma interferon protects endothelial cells from damage by Candida albicans by inhibiting endothelial cell phagocytosis
101. Growth inhibition of Candida albicans by vaginal cells from naive mice
102. Differential susceptibility to experimental vaginal candidiasis in macaques
103. Effects of reproductive hormones on experimental vaginal candidiasis
104. Growth inhibition of Candida albicans by human vaginal epithelial cells
105. Oral mycoses in HIV infection
106. Pathology and clinical correlates in oral candidiasis and its variants: A review
107. Oral manifestations of HIV infection: Definitions, diagnostic criteria and principles of therapy
108. Oral lesions among women living with or at risk for HIV infection
109. Effect of cigarette smoking on HIV-related oral lesions
110. Effect of smoking on the clinical progression of HIV-1 infection
111. Oral mucosal lesions and HIV viral load in the Women's interagency HIV study (WIHS)
112. + patients may influence the selection of HIV-1 protease variants
113. Proliferative and cytotoxic responses to mannoproteins of Candida albicans by peripheral blood lymphocytes of HIV-infected subjects
114. Histopathologic and ultrastructural studies of oral mucosa with Candida infection
115. Experimental oral candidiasis in animal models
116. Colonization of congenitally athymic, gnotobiotic mice by Candida albicans
117. Correlates of cell-mediated immunity in Candida albicans- colonized gnotobiotic mice
118. Acquired immunity to systemic candidiasis in immunodeficient mice
119. Mucosal and disseminated candidiasis in gnotobiotic SCID mice
120. Comparison of a lesion-inducing isolate and a non-lesional isolate of Candida albicans in an immunosuppressed rat model of oral candidiasis
121. d) mice
122. CD29 expression on CD4+ gingival lymphocytes supports migration of activated memory T lymphocytes to diseased periodontal tissue
123. CD30+ lymphocytes in chronic gingivitis from HIV-positive patients: A pilot study
124. Oral carriage of Candida albicans in murine AIDS
125. Growth inhibition of Candida albicans by interleukin-2-induced lymph node cells
126. Growth inhibition of Candida albicans hyphae by CD8+ lymphocytes
127. Recognition of antigenic clusters of Candida albicans by T lymphocytes from human immunodeficiency virus-infected persons
128. Cellular and cytokine correlates of mucosal protection in murine model of oral candidiasis
129. + T lymphocytes in recovery from oropharyngeal candidiasis
130. Irradiation-induced oral candidiasis in an experimental murine model
131. Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: A pilot study in HIV-positive individuals with oropharyngeal candidiasis
132. Salivary cytokine profiles in the immunocompetent individual with Candida-associated denture stomatitis
133. Cytokine expression in periodontal health and disease
134. Immunohistological analysis of T cell functional subsets in chronic inflammatory periodontal disease
135. Cytokines in the saliva of HIV-positive individuals with and without periodontal disease
136. High numbers of T cells in gingiva from patients with human immunodeficiency virus (HIV) infection
137. A comparison of T4: T8 lymphocyte ratio in the periodontal lesion of healthy and HIV-positive patients
138. Anti-fungal and cytokine producing activities of CD8+ T lymphocytes from HIV-1 infected individuals
139. CD8 cell noncytotoxic antiviral activity in human immunodeficiency virus-infected and -uninfected children
140. Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response
141. Immunocompetent cells in oral candidiasis of HIV-infected patients: An immunohistochemical and electron microscopical study
142. Characterisation of the inflammatory cell infiltrate in chronic hyperplastic candidosis of the oral mucosa
143. Immunoglobulin A (IgA), IgA1, and IgA2 antibodies to Candida albicans in whole and parotid saliva in human immunodeficiency virus infection and AIDS
144. Salivary and mucosal immune responses to HIV and its co-pathogens
145. Whole and parotid saliva IgA and IgA-subclass responses to Candida albicans in HIV infection
146. Longitudinal study of anti-Candida albicans mucosal immunity against aspartic proteinases in HIV-infected patients
147. Alteration of humoral responses to Candida in HIV infection
148. A comprehensive study of Candida-specific antibodies in saliva of HIV-infected persons with oropharyngeal candidiasis
149. T cells augment monocyte and neutrophil function in host resistance against oropharyngeal candidiasis
150. Growth inhibition of Candida by human oral epithelial cells
151. Cytokine and chemokine production by human oral and vaginal epithelial cells in response to Candida albicans
152. Candida albicans triggers interleukin-6 and interleukin-8 responses by oral fibroblasts in vitro
153. Epithelial antimicrobial peptides: Review and significance for oral applications
154. Anticandidal activity of major human salivary histatins
155. The leucocyte protein L1 (calprotectin): A putative nonspecific defence factor at epithelial surfaces
156. Oral candidiasis established in the sialoadenectomised rat
157. Oral and esophageal Candida albicans infection in hyposalivatory rats
158. Further characterization of human salivary anticandidal activities in a human immunodeficiency virue-positive cohort by use of microarrays
159. Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans